



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/893,604	06/29/2001	Robert A. Hallowitz	BIOT1-11	6514

33449 7590 07/15/2003

BIO-TECH IMAGING, INC.  
5711 INDUSRTY LANE UNIT 31  
FREDERICK, MD 21704

EXAMINER

PARKIN, JEFFREY S

ART UNIT	PAPER NUMBER
----------	--------------

1648

DATE MAILED: 07/15/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/893,604

Applicant(s)

HALLOWITZ ET AL.

Examiner

Jeffrey S. Parkin, Ph.D.

Art Unit

1648

– The MAILING DATE of this communication appears on the cover sheet with the correspondence address –  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 03 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 29 June 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-16 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

Detailed Office Action

*Status of the Claims*

1. Claims 1-16 are pending in the instant application.

*35 U.S.C. § 103(a)*

2. The following is a quotation of 35 U.S.C. § 103(a) which forms  
the basis for all obviousness rejections set forth in this Office  
action:

(a) A patent may not be obtained though the invention is not  
identically disclosed or described as set forth in section 102 of  
this title, if the differences between the subject matter sought to  
be patented and the prior art are such that the subject matter as  
a whole would have been obvious at the time the invention was made  
to a person having ordinary skill in the art to which said subject  
matter pertains. Patentability shall not be negated by the manner  
in which the invention was made.

Subject matter developed by another person, which qualifies as  
prior art only under subsection (f) or (g) of section 102 of this  
title, shall not preclude patentability under this section where the  
subject matter and the claimed invention were, at the time the  
invention was made, owned by the same person or subject to an  
obligation of assignment to the same person.

3. This application currently names joint inventors. In  
considering patentability of the claims under 35 U.S.C. § 103(a),  
the examiner presumes that the subject matter of the various claims  
was commonly owned at the time any inventions covered therein were  
made absent any evidence to the contrary. Applicant is advised of  
the obligation under 37 C.F.R. § 1.56 to point out the inventor and  
invention dates of each claim that was not commonly owned at the  
time a later invention was made in order for the examiner to  
consider the applicability of 35 U.S.C. § 103(c) and potential 35  
U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103(a).

4. Claims 1-10 are rejected under 35 U.S.C. § 103(a) as being  
unpatentable over Connelly et al. (1997) in view of King and

Hallowitz (1998). Connelly et al. (1997) provide methods for the detection of HIV-1-infected cells employing a viral specific antibody (anti-p24) and a T-lymphocyte specific antibody (anti-CD4) to ascertain the infectivity status of any given patient (see  
5 claims, cols. 36-38). Various art-recognized methodologies for detecting the antigens of interest are disclosed throughout the body of the patent. This teaching does not disclose a diagnostic assay employing both a CD4-specific marker and gp120-specific marker. However, King and Hallowitz (1998) provide magnetic  
10 particle assays to detect gp120 on the surface of infected cells (see cols. 9 and 10). Therefore, it would it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to assess the infectivity status of an infected patient by ascertaining the number of CD4<sup>+</sup> cells, as  
15 taught by Connelly et al. (1997), that express a gp120 on the cell surface, as provided by King and Hallowitz (1998), since this would provide a rapid and facile method for assessing the patient's infectivity status. Comparing the number of gp120<sup>+</sup> cells to the number of CD4<sup>+</sup> cells would allow the skilled clinician to assess  
20 which therapeutic regimens would prove most useful.

**35 U.S.C. § 112, First Paragraph**

5. The following is a quotation of the first paragraph of 35 U.S.C. § 112:

25       The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most  
30       nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 11-16 are rejected under 35 U.S.C. § 112, first  
35 paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art

to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The claims are directed toward methods of determining the infectivity status of a host who is presumably infected with HIV, but who has tested negative in virus coculture assays, by measuring cell-surface gp120 and the fraction of CD4<sup>+</sup> cells that carry the viral antigen.

The legal considerations that govern enablement determinations pertaining to undue experimentation are disclosed in *In re Wands*, 8 U.S.P.Q.2d 1400 (C.A.F.C. 1988) and *Ex parte Forman* 230 U.S.P.Q. 546 (PTO Bd. Pat. App. Int., 1986). The courts concluded that several factual inquiries should be considered when making such assessments including the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in that art, the predictability or unpredictability of the art and the breadth of the claims. *In re Rainer*, 52 C.C.P.A. 1593, 347 F.2d 574, 146 U.S.P.Q. 218 (1965). The disclosure fails to provide adequate guidance pertaining to a number of these considerations as follows:

The disclosure fails to provide adequate guidance pertaining to the sensitivity of the claimed methodology. The patient has already tested negative by at least one standard virological assay. Thus, it is not readily manifest, absent further manipulation to the patients PBMCs, that a sufficient number of cells expressing cell-surface gp120 are present in the patient. The coculture assay initially employed relies upon the expression of gp120. Since the assay was negative, the skilled artisan could reasonably assume that such patients are expressing minute quantities of antigen, if any. Accordingly, simply using an antibody-based assay, absent further sample manipulation, would not be expected to produce the desired result. The disclosure fails to provide any guidance or working embodiments addressing this concern. Thus, the skilled

artisan would reasonably conclude the claimed methodology lacks the requisite sensitivity to detect HIV-1 infection in seronegative patients.

5

*Correspondence*

7. The Art Unit location of your application in the Patent and Trademark Office has changed. To facilitate the correlation of related papers and documents for this application, all future correspondence should be directed to **art unit 1648**.

10

8. Correspondence related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward one of the following Group 1600 fax numbers: (703) 308-4242 or (703) 305-3014. Informal communications may be submitted directly to the Examiner through the following fax number: (703) 308-4426. Applicants are encouraged to notify the Examiner prior to the submission of such documents to facilitate their expeditious processing and entry.

15


20

9. Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (703) 308-2227. The examiner can normally be reached Monday through Thursday from 8:30 AM to 6:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisors, Laurie Scheiner or James Housel, can be reached at (703) 308-1122 or (703) 308-4027, respectively. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

25

30

Respectfully,

  
Jeffrey S. Parkin, Ph.D.  
Patent Examiner  
Art Unit 1648

10 July, 2003